LAKE FOREST, Ill., June 3, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today results from a post-marketing study of the company's European biosimilar epoetin, Retacrit™. This prospective, observational study met the primary endpoint, as defined by hemoglobin treatment response, in the management of chemotherapy-induced anemia in adult patients with solid tumors, lymphomas and myelomas, regardless of chemotherapy cycle. Retacrit was well tolerated by patients in the study. Full results of the study, called ORHEO (place of biOsimilaRs in the therapeutic management of anemia secondary to chemotherapy in HEmatology and Oncology), were presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 3 (Abstract 9564).
Retacrit, a recombinant human erythropoietin, or an "EPO biosimilar," was launched in Europe in early 2008. Retacrit is used to treat symptomatic anemia associated with chronic renal failure in adult and pediatric patients and anemia in adult patients receiving chemotherapy for solid tumors, malignant lymphoma or multiple myeloma.
Patients with chemotherapy-induced anemia (Hb <110 g/L), greater than 18 years old, with solid tumors, lymphomas or myelomas and eligible for epoetin alfa treatment were included in the study. The primary endpoint was the rate of response (defined as an increase in Hb levels to 100 g/L or at least 10 g/L since inclusion visit, or reaching target Hb set at start of study, without any blood transfusions in the three weeks prior to measurement) at plus three months (M3). Other endpoints included rate of response at plus six months (M6) and safety endpoints.
|SOURCE Hospira, Inc.|
Copyright©2012 PR Newswire.
All rights reserved